Related Experiment Video
Updated: May 24, 2025
11:15
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
10.1K
Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastases
Debora M Meijer1, Siddh van Oost2, Jessica P Roelands1
1Department of Pathology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
BMJ Oncology
|March 6, 2025
Summary
Metastatic osteosarcoma shows increased T cell immunity and cancer testis antigen expression, particularly MAGEA. This suggests MAGEA antigens are promising targets for novel immunotherapies in advanced osteosarcoma treatment.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Osteosarcoma is the most common primary bone cancer.
- Metastatic disease affects 50% of patients, with poor 5-year survival rates (20-30%).
- Current immunotherapies show limited efficacy in osteosarcoma.
Purpose of the Study:
- To explore novel immunotherapeutic strategies for advanced osteosarcoma.
- To characterize the immunogenomic landscape of osteosarcoma during disease progression.
Main Methods:
- Immunogenomic characterization of 30 osteosarcoma samples from seven patients.
- RNA-sequencing and imaging mass cytometry analysis.
- Validation in an independent cohort (N=91).
Main Results:
- Enriched cytotoxic T cell-driven immunity in metastatic lesions compared to primary tumors.
- T cells infiltrated metastases, indicating no immune exclusion.
- Increased expression of cancer testis antigens, especially MAGEA, in metastases, validated independently.
- MAGE-derived peptides presented in osteosarcoma cell lines.
Conclusions:
- Cytotoxic immune responses and MAGEA antigen expression are augmented from primary to metastatic osteosarcoma.
- MAGEA antigens represent potential therapeutic targets for advanced osteosarcoma immunotherapy.
